Previously, we have shown that class I p21-activated serine/threonine kinases (PAKs) remained active in TKI-naive and TKI-treated CML-CP leukemia stem and early progenitor cells. This evidence concerns the gene MARK2 and chronic myelogenous leukemia, BCR-ABL1 positive.